Watchlist Price Alert

Dyne Therapeutics Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD

11.38

1.98 (21.06%)

At close: May 08, 2025, 12:59 PM

21.06% (1D)

Bid	11.32
Market Cap	1.29B
Revenue (ttm)	n/a
Net Income (ttm)	-317.42M
EPS (ttm)	-3.37
PE Ratio (ttm)	-3.38
Forward PE	-2.73
Analyst	Buy

Ask	11.39
Volume	3,360,212
Avg. Volume (20D)	2,239,104
Open	9.58
Previous Close	9.40
Day's Range	9.26 - 11.78
52-Week Range	6.36 - 47.45
Beta	1.19

About DYN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DYN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DYN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

-15.3%

Shares of vaccine and gene therapy stocks are trad... Unlock content with Pro Subscription

3 months ago

-2.98%

Dyne Therapeutics shares are trading higher after the company announced it received FDA Fast Track designation for DYNE-101 to treat myotonic dystrophy type 1.

News

1 month ago · seekingalpha.com

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, us...

2 months ago · zacks.com

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r...